High-Surface-Area Lyophilized Arsenic Trioxide for Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional arsenic trioxide treatment for hematological malignancies requires daily intravenous administration, which is inconvenient, risky, and expensive, and there is no FDA-approved oral formulation, due to its insolubility and low bioavailability.
Innovation Solution
A lyophilized composition comprising arsenic trioxide is developed, which is solubilized and lyophilized to enhance bioavailability, allowing oral administration in the form of capsules or tablets, with a method involving alkalization, acidification, and freeze-drying processes to create a stable and effective oral formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous administration of arsenic trioxide is used, then therapeutic efficacy is achieved, but treatment convenience and patient quality of life deteriorate
Solution Approach 1:
The patent changes the physical and chemical parameters of arsenic trioxide by converting it from an insoluble crystalline form to a soluble lyophilized formulation. This involves dissolving arsenic trioxide in alkaline solution, adjusting pH, and performing freeze-drying to create a highly soluble powder that can be orally administered, thereby improving treatment convenience while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining arsenic trioxide with alkaline agents (such as sodium bicarbonate or citrate buffers) and lyoprotectants (such as mannitol or sucrose). This composite approach enhances solubility and stability, enabling oral administration while preserving the therapeutic activity of arsenic trioxide
2Reliability
If intravenous administration of arsenic trioxide is used, then therapeutic effect is achieved, but treatment cost and risk increase
Solution Approach 1:
The patent extracts the active therapeutic component (arsenic trioxide) from its conventional intravenous formulation and isolates it in a purified, lyophilized form. This extraction allows the drug to be delivered through a simpler oral route, eliminating the need for complex intravenous administration infrastructure and reducing treatment costs while maintaining therapeutic effectiveness
3Ease of operation
If oral formulation of arsenic trioxide is developed, then treatment convenience improves, but bioavailability and solubility worsen
Solution Approach 1:
The patent dramatically changes the solubility parameter of arsenic trioxide by dissolving it in alkaline solution (pH 10-12) followed by pH adjustment and freeze-drying. This process creates a lyophilized powder with enhanced solubility and bioavailability, ensuring that oral administration achieves sufficient drug absorption while maintaining treatment convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lyophilized arsenic trioxide formulation provides systemic bioavailability comparable to intravenous administration, offering a convenient, less risky, and cost-effective treatment option for hematological malignancies with improved patient compliance and quality of life.
Implementation Method 1
A lyophilized composition comprising arsenic trioxide is developed, which is solubilized and lyophilized to enhance bioavailability
Implementation Method 2
lyophilized composition comprising arsenic trioxide is developed, which is solubilized and lyophilized
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.